2026 Q1 -tulosraportti
Vain PDF
107 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 25.8.2025 | ||
2025 Q1 -tulosraportti 28.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·17 t sittenWho are upcoming candidates to acquire BI. Yes, as has been written about several times, these BP are probably the main candidates: 1) Merck 2) AstraZeneca 3) Bristol Myers Squibb (BMS) 4) Roche, presumably in that order but I have argued several times for a Japanese Dark Horse; the arrow (mine) also points to Daiichi Sankyo, because they have a unique strategic overlap with BioInvent, which no other Japanese players match. Their focus on ADC-development makes them particularly interested in technologies that can strengthen the antibody-effect — precisely what BI-1206 does via FcγRIIB-inhibition. At the same time, they are actively seeking new immuno-oncological targets, where BioInvent's F.I.R.S.T-platform fits perfectly. It is this combination that makes Daiichi Sankyo the most logical Japanese candidate. But 1 and 2 are almost expected, but I really hope D.S. enters the scene. That would lead to extra board meetings at Merck and Astra, a bit cool. Yes, and if Merck is overtaken, they will have helped finance a product that a competitor can snatch and further develop, a cool thought. If D.S. makes an offer, Merck will almost 100% guarantee come with a counter-offer. Imagine if D.S. subsequently, via other partners, goes in and makes a generic version of Keytruda with BI optimized .. wow
·15.6.this case has certainly developed in a negative direction is it the fear that they will run out of money they do have a huge cash burn that makes people want to get out last Monday price 29.65 and now 22.5 almost 25 % down bad bad developmentIt is strange. But AstraZeneca is also falling after FDA approval of a drug against prostate cancer today. And AstraZeneca is rock-solid.- 12.6.Summary fra Redeye d.d.: Summary The main lesson we take away from the KOL event is the importance of a clean safety profile. Both BI-1808 in CTCL and the triplet (including BI-1206) in NHL have a class-leading safety profile, while efficacy is up there with the best competing alternatives. While both advanced-line lymphoma treatments and CTCL have several effective treatment modalities, they are all comparatively tough on the patient, which impacts patient quality of life since the diseases are chronic with long survivals. BioInvent is carving out a smart niche focused on treatments with high efficacy and low toxicity, translating into outpatient manageability in the case of lymphoma. Both BI-1808 and BI-1206 are partnering candidates in the near to medium term. BI-1206 is already positioned and ready for partnering in lymphoma, while some additional data are needed for solid indications. A deal in solid tumours will bring in a larger deal, so it can make sense to wait for the NSCLC data that will start coming in in H2. The case is similar for BI-1808, for which the potential is much larger in solid indications, while CTCL represent a be an express route to market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
107 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sittenWho are upcoming candidates to acquire BI. Yes, as has been written about several times, these BP are probably the main candidates: 1) Merck 2) AstraZeneca 3) Bristol Myers Squibb (BMS) 4) Roche, presumably in that order but I have argued several times for a Japanese Dark Horse; the arrow (mine) also points to Daiichi Sankyo, because they have a unique strategic overlap with BioInvent, which no other Japanese players match. Their focus on ADC-development makes them particularly interested in technologies that can strengthen the antibody-effect — precisely what BI-1206 does via FcγRIIB-inhibition. At the same time, they are actively seeking new immuno-oncological targets, where BioInvent's F.I.R.S.T-platform fits perfectly. It is this combination that makes Daiichi Sankyo the most logical Japanese candidate. But 1 and 2 are almost expected, but I really hope D.S. enters the scene. That would lead to extra board meetings at Merck and Astra, a bit cool. Yes, and if Merck is overtaken, they will have helped finance a product that a competitor can snatch and further develop, a cool thought. If D.S. makes an offer, Merck will almost 100% guarantee come with a counter-offer. Imagine if D.S. subsequently, via other partners, goes in and makes a generic version of Keytruda with BI optimized .. wow
- ·15.6.this case has certainly developed in a negative direction is it the fear that they will run out of money they do have a huge cash burn that makes people want to get out last Monday price 29.65 and now 22.5 almost 25 % down bad bad developmentIt is strange. But AstraZeneca is also falling after FDA approval of a drug against prostate cancer today. And AstraZeneca is rock-solid.
- 12.6.Summary fra Redeye d.d.: Summary The main lesson we take away from the KOL event is the importance of a clean safety profile. Both BI-1808 in CTCL and the triplet (including BI-1206) in NHL have a class-leading safety profile, while efficacy is up there with the best competing alternatives. While both advanced-line lymphoma treatments and CTCL have several effective treatment modalities, they are all comparatively tough on the patient, which impacts patient quality of life since the diseases are chronic with long survivals. BioInvent is carving out a smart niche focused on treatments with high efficacy and low toxicity, translating into outpatient manageability in the case of lymphoma. Both BI-1808 and BI-1206 are partnering candidates in the near to medium term. BI-1206 is already positioned and ready for partnering in lymphoma, while some additional data are needed for solid indications. A deal in solid tumours will bring in a larger deal, so it can make sense to wait for the NSCLC data that will start coming in in H2. The case is similar for BI-1808, for which the potential is much larger in solid indications, while CTCL represent a be an express route to market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 25.8.2025 | ||
2025 Q1 -tulosraportti 28.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
107 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 25.8.2025 | ||
2025 Q1 -tulosraportti 28.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sittenWho are upcoming candidates to acquire BI. Yes, as has been written about several times, these BP are probably the main candidates: 1) Merck 2) AstraZeneca 3) Bristol Myers Squibb (BMS) 4) Roche, presumably in that order but I have argued several times for a Japanese Dark Horse; the arrow (mine) also points to Daiichi Sankyo, because they have a unique strategic overlap with BioInvent, which no other Japanese players match. Their focus on ADC-development makes them particularly interested in technologies that can strengthen the antibody-effect — precisely what BI-1206 does via FcγRIIB-inhibition. At the same time, they are actively seeking new immuno-oncological targets, where BioInvent's F.I.R.S.T-platform fits perfectly. It is this combination that makes Daiichi Sankyo the most logical Japanese candidate. But 1 and 2 are almost expected, but I really hope D.S. enters the scene. That would lead to extra board meetings at Merck and Astra, a bit cool. Yes, and if Merck is overtaken, they will have helped finance a product that a competitor can snatch and further develop, a cool thought. If D.S. makes an offer, Merck will almost 100% guarantee come with a counter-offer. Imagine if D.S. subsequently, via other partners, goes in and makes a generic version of Keytruda with BI optimized .. wow
- ·15.6.this case has certainly developed in a negative direction is it the fear that they will run out of money they do have a huge cash burn that makes people want to get out last Monday price 29.65 and now 22.5 almost 25 % down bad bad developmentIt is strange. But AstraZeneca is also falling after FDA approval of a drug against prostate cancer today. And AstraZeneca is rock-solid.
- 12.6.Summary fra Redeye d.d.: Summary The main lesson we take away from the KOL event is the importance of a clean safety profile. Both BI-1808 in CTCL and the triplet (including BI-1206) in NHL have a class-leading safety profile, while efficacy is up there with the best competing alternatives. While both advanced-line lymphoma treatments and CTCL have several effective treatment modalities, they are all comparatively tough on the patient, which impacts patient quality of life since the diseases are chronic with long survivals. BioInvent is carving out a smart niche focused on treatments with high efficacy and low toxicity, translating into outpatient manageability in the case of lymphoma. Both BI-1808 and BI-1206 are partnering candidates in the near to medium term. BI-1206 is already positioned and ready for partnering in lymphoma, while some additional data are needed for solid indications. A deal in solid tumours will bring in a larger deal, so it can make sense to wait for the NSCLC data that will start coming in in H2. The case is similar for BI-1808, for which the potential is much larger in solid indications, while CTCL represent a be an express route to market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt